85 related articles for article (PubMed ID: 23369680)
1. Towards individualised treatment in ovarian cancer.
Mahner S; Pfisterer J
Lancet Oncol; 2013 Feb; 14(2):101-2. PubMed ID: 23369680
[No Abstract] [Full Text] [Related]
2. Selumetinib in women with recurrent low-grade serous carcinoma of the ovary or peritoneum: an open-label, single-arm, phase 2 study.
Farley J; Brady WE; Vathipadiekal V; Lankes HA; Coleman R; Morgan MA; Mannel R; Yamada SD; Mutch D; Rodgers WH; Birrer M; Gershenson DM
Lancet Oncol; 2013 Feb; 14(2):134-40. PubMed ID: 23261356
[TBL] [Abstract][Full Text] [Related]
3. Papillary serous cystadenocarcinoma of the stomach, peritoneum and ovary.
Yen CC; Tsai CS; Hsi SC; Yang YS
Acta Gastroenterol Belg; 2009; 72(4):462. PubMed ID: 20163045
[No Abstract] [Full Text] [Related]
4. MEK Inhibitors for the Treatment of Low-Grade Serous Ovarian Cancer: Expanding Therapeutic Options for a Rare Ovarian Cancer Subtype.
Gershenson DM; Gourley C; Paul J
J Clin Oncol; 2020 Nov; 38(32):3731-3734. PubMed ID: 32897828
[No Abstract] [Full Text] [Related]
5. MAP3K8/TPL-2/COT is a potential predictive marker for MEK inhibitor treatment in high-grade serous ovarian carcinomas.
Gruosso T; Garnier C; Abelanet S; Kieffer Y; Lemesre V; Bellanger D; Bieche I; Marangoni E; Sastre-Garau X; Mieulet V; Mechta-Grigoriou F
Nat Commun; 2015 Oct; 6():8583. PubMed ID: 26456302
[TBL] [Abstract][Full Text] [Related]
6. Ovarian and papillary-serous peritoneal carcinoma: pilot study with thalidomide.
Abramson N; Stokes PK; Luke M; Marks AR; Harris JM
J Clin Oncol; 2002 Feb; 20(4):1147-9. PubMed ID: 11844842
[No Abstract] [Full Text] [Related]
7. Prolonged response to aflibercept in ovarian cancer relapse: a case report.
Redondo A; Castelo B; Pinto A; Zamora P; Espinosa E
Tumori; 2015 Mar; 101(1):e29-31. PubMed ID: 25702661
[TBL] [Abstract][Full Text] [Related]
8. Secondary surgery in patients with serous low malignant potential ovarian tumors with peritoneal implants.
Kane A; Uzan C; Rey A; Gouy S; Duvillard P; Morice P
Int J Gynecol Cancer; 2010 Apr; 20(3):346-52. PubMed ID: 20375795
[TBL] [Abstract][Full Text] [Related]
9. Phase 1 and 2 study of carboplatin and pralatrexate in patients with recurrent, platinum-sensitive ovarian, fallopian tube, or primary peritoneal cancer.
Del Carmen MG; Supko JG; Horick NK; Rauh-Hain JA; Clark RM; Campos SM; Krasner CN; Atkinson T; Birrer MJ
Cancer; 2016 Nov; 122(21):3297-3306. PubMed ID: 27421044
[TBL] [Abstract][Full Text] [Related]
10. Evaluation of monoclonal humanized anti-HER2 antibody, trastuzumab, in patients with recurrent or refractory ovarian or primary peritoneal carcinoma with overexpression of HER2: a phase II trial of the Gynecologic Oncology Group.
Bookman MA; Darcy KM; Clarke-Pearson D; Boothby RA; Horowitz IR
J Clin Oncol; 2003 Jan; 21(2):283-90. PubMed ID: 12525520
[TBL] [Abstract][Full Text] [Related]
11. Weekly topotecan for recurrent ovarian, fallopian tube and primary peritoneal carcinoma: tolerability and efficacy study--the Israeli experience.
Safra T; Berman T; Yachnin A; Bruchim I; Meirovitz M; Barak F; Atlas I; Levy T; Rosengarten OS
Int J Gynecol Cancer; 2013 Mar; 23(3):475-80. PubMed ID: 23435437
[TBL] [Abstract][Full Text] [Related]
12. Is there a taxane-free interval that predicts response to taxanes as a later-line treatment of recurrent ovarian or primary peritoneal cancer?
McCourt C; Dessie S; Bradley AM; Schwartz J; Brard L; Dizon DS
Int J Gynecol Cancer; 2009 Apr; 19(3):343-7. PubMed ID: 19407557
[TBL] [Abstract][Full Text] [Related]
13. Treatment of chemotherapy-induced anemia in ovarian cancer patients: does the use of erythropoiesis-stimulating agents worsen survival?
Rocconi RP; Sullivan P; Long B; Blaize M; Brown J; Arbuckle J; Bevis K; Estes JM; Reed E; Finan MA
Int J Gynecol Cancer; 2012 Jun; 22(5):786-91. PubMed ID: 22552832
[TBL] [Abstract][Full Text] [Related]
14. Phase II trial of imatinib mesylate in patients with recurrent platinum- and taxane-resistant low-grade serous carcinoma of the ovary, peritoneum, or fallopian tube.
Noguera IR; Sun CC; Broaddus RR; Branham D; Levenback CF; Ramirez PT; Sood AK; Coleman RL; Gershenson DM
Gynecol Oncol; 2012 Jun; 125(3):640-5. PubMed ID: 22387451
[TBL] [Abstract][Full Text] [Related]
15. Successful pregnancy in a patient with pseudomyxoma peritonei arising from ovarian mucinous cystadenocarcinoma treated with cisplatin.
Niwa K; Morishita S; Murase T; Kawabata I; Imai A; Shimokawa K; Tamaya T
Gynecol Oncol; 1995 Dec; 59(3):398-400. PubMed ID: 8522263
[TBL] [Abstract][Full Text] [Related]
16. Safety and Antitumor Activity of Anti-PD-1 Antibody, Nivolumab, in Patients With Platinum-Resistant Ovarian Cancer.
Hamanishi J; Mandai M; Ikeda T; Minami M; Kawaguchi A; Murayama T; Kanai M; Mori Y; Matsumoto S; Chikuma S; Matsumura N; Abiko K; Baba T; Yamaguchi K; Ueda A; Hosoe Y; Morita S; Yokode M; Shimizu A; Honjo T; Konishi I
J Clin Oncol; 2015 Dec; 33(34):4015-22. PubMed ID: 26351349
[TBL] [Abstract][Full Text] [Related]
17. Prognostic significance of rising serum CA-125 levels within the normal range in patients with epithelial ovarian, primary peritoneal, and tubal cancers, who, after initial treatment, had a complete clinical response.
Levy T; Weiser R; Boaz M; Shem EB; Golan A; Menczer J
Int J Gynecol Cancer; 2012 Oct; 22(8):1344-8. PubMed ID: 22954785
[TBL] [Abstract][Full Text] [Related]
18. What is the benefit of bevacizumab combined with chemotherapy in patients with recurrent ovarian, fallopian tube or primary peritoneal malignancies?
Cheng X; Moroney JW; Levenback CF; Fu S; Jaishuen A; Kavanagh JJ
J Chemother; 2009 Nov; 21(5):566-72. PubMed ID: 19933049
[TBL] [Abstract][Full Text] [Related]
19. Improved survival trends in platinum-resistant patients with advanced ovarian, fallopian or peritoneal cancer treated with first-line paclitaxel/platinum chemotherapy: the impact of novel agents.
Bamias A; Bamia C; Zagouri F; Kostouros E; Kakoyianni K; Rodolakis A; Vlahos G; Haidopoulos D; Thomakos N; Antsaklis A; Dimopoulos MA
Oncology; 2013; 84(3):158-65. PubMed ID: 23296063
[TBL] [Abstract][Full Text] [Related]
20. Impact of complete cytoreduction leaving no gross residual disease associated with radical cytoreductive surgical procedures on survival in advanced ovarian cancer.
Chang SJ; Bristow RE; Ryu HS
Ann Surg Oncol; 2012 Dec; 19(13):4059-67. PubMed ID: 22766983
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]